Kevin J. Tracey

Feinstein Institutes Scientists Observe Vagus Nerve Stimulation Effect on Brain Activity

Retrieved on:

Tuesday, June 22, 2021

Health, Hospitals, Surgery, General Health, Research, Science, Branches of biology, Anatomy, Neuroscience, Electrotherapy, Abdomen, Autonomic nervous system, Gustatory system, Vagus nerve, Kevin J. Tracey, Neurostimulation, Vagus nerve stimulation, Management of drug-resistant epilepsy

The vagus nerve is a major therapeutic target for the emerging field of bioelectronic medicine, which uses neurostimulation to treat diseases.

Key Points:

The vagus nerve is a major therapeutic target for the emerging field of bioelectronic medicine, which uses neurostimulation to treat diseases.
Electrically stimulating the vagus nerve is approved by the Food and Drug Administration as a non-pharmacological treatment for brain diseases, including epilepsy and depression.
While the links between the vagus nerve, body and the brain are well documented, the effects of VNS on brain function are complex and only partially understood.
The brain monitors and controls healthy organ function because it receives and processes information in the vagus nerve, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.

Feinstein Institutes Receives $3.7M NIH Support for Bioelectronic Medicine Research

Retrieved on:

Thursday, May 6, 2021

Health, Managed care, Clinical trials, Research, Science, Biotechnology, Feinstein Institute for Medical Research, Manhasset, New York, Academic journals, National Institutes of Health, National Institute of General Medical Sciences, Kevin J. Tracey, Medical research, Molecular Medicine, Health care, Health

b'The Feinstein Institutes for Medical Research , the global scientific home of bioelectronic medicine , has been awarded a five-year grant totaling more than $3.7 million from the National Institutes of Health\xe2\x80\x99s (NIH) National Institute of General Medical Sciences (NIGMS) to support research in the molecular basis of bioelectronic medicine.

Key Points:

b'The Feinstein Institutes for Medical Research , the global scientific home of bioelectronic medicine , has been awarded a five-year grant totaling more than $3.7 million from the National Institutes of Health\xe2\x80\x99s (NIH) National Institute of General Medical Sciences (NIGMS) to support research in the molecular basis of bioelectronic medicine.
View the full release here: https://www.businesswire.com/news/home/20210506005048/en/\nKevin J. Tracey, MD, president and CEO of the Feinstein Institutes.
(Credit: The Feinstein Institutes for Medical Research)\nBioelectronic medicine explores the use of electronic devices to treat disease and injury through the body\xe2\x80\x99s nervous system instead of pharmaceuticals.
Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.

New Schizophrenia Genetic Mutation Discovered by Feinstein Institutes Researchers

Retrieved on:

Monday, March 22, 2021

Research, Mental health, Genetics, Clinical trials, Other Health, Biotechnology, General Health, Health, Science, Oncology, Feinstein Institute for Medical Research, Manhasset, New York, Northwell Health, Schizophrenia, Kevin J. Tracey, Medical specialties, Mind, Health care

Researchers at The Feinstein Institutes for Medical Research , in collaboration with Columbia University, have identified a gene mutation that could result in schizophrenia, a chronic brain disorder that affects nearly one percent of the worlds population .

Key Points:

Researchers at The Feinstein Institutes for Medical Research , in collaboration with Columbia University, have identified a gene mutation that could result in schizophrenia, a chronic brain disorder that affects nearly one percent of the worlds population .
View the full release here: https://www.businesswire.com/news/home/20210322005589/en/
Todd Lencz, professor in the Institute of Behavioral Science at the Feinstein Institutes.
Dr. Lenczs research into the role of genetics in schizophrenia offers a major advance, said Kevin J. Tracey, MD president and CEO of the Feinstein Institutes.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.

Feinstein Institutes to Host Responsible Conduct of Research During a Pandemic Conference

Retrieved on:

Friday, February 5, 2021

The Feinstein Institutes for Medical Research will host Driving Responsible Conduct of Research During a Pandemic, a virtual conference highlighting the challenges and lessons learned in conducting high quality, ethical clinical and translational research during a pandemic.

Key Points:

The Feinstein Institutes for Medical Research will host Driving Responsible Conduct of Research During a Pandemic, a virtual conference highlighting the challenges and lessons learned in conducting high quality, ethical clinical and translational research during a pandemic.
View the full release here: https://www.businesswire.com/news/home/20210205005350/en/
Bettie M. Steinberg, PhD, (right) of the Feinstein Institutes is co-chair of the conference.
The COVID-19 pandemic created significant challenges to conducting research, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.

Study Supports Bioelectronic Medicine to Treat Rheumatoid Arthritis

Retrieved on:

Tuesday, February 2, 2021

The burgeoning scientific field of bioelectronic medicine , which features the use of electronic devices to stimulate nerves to treat disease, has shown great promise in alleviating serious health conditions.

Key Points:

The burgeoning scientific field of bioelectronic medicine , which features the use of electronic devices to stimulate nerves to treat disease, has shown great promise in alleviating serious health conditions.
In a Lancet Rheumatology editorial published , Feinstein Institutes for Medical Research president and CEO Kevin J. Tracey, MD , discussed a recent clinical study that used a hand-held battery-operated electronic device to treat patients suffering from moderate to severe rheumatoid arthritis (RA).
The Feinstein Institutes for Medical Research is known as the global scientific home of bioelectronic medicine.
Bioelectronic medicine combines molecular medicine, neuroscience, and biomedical engineering to develop innovative therapies to treat various diseases and conditions through targeted stimulation of nerves, including paralysis, arthritis, pulmonary hypertension, and inflammatory bowel disease.

Comparative Analysis of COVID-19 Reveals a Cytokine Shower, Not a Storm

Retrieved on:

Monday, October 19, 2020

Research, Infectious diseases, Hospitals, Health, University, Other Science, Science, Education, Oncology, Medical specialties, Immunology, Health, Coronavirus disease, Cytokine storm, Cytokine, Kevin J. Tracey

However, new research from The Feinstein Institutes for Medical Research indicates that COVID-19 does not cause cytokine storms.

Key Points:

However, new research from The Feinstein Institutes for Medical Research indicates that COVID-19 does not cause cytokine storms.
The results suggest a potential alternate course of treatments as many clinicians have regularly prescribed anti-cytokine therapies to treat COVID-19.
Our understanding of the cytokine responses in COVID-19 continues to evolve, said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes.
Dr. Deutschmans team findings show that a cautious approach is needed to potentially manipulate cytokine levels with drugs.

Fourth Bioelectronic Medicine Summit Showcases Broad Innovation

Retrieved on:

Monday, September 28, 2020

Biotechnology, Technology, Other Health, Health, General Health, Radiology, Other Science, Other Technology, Medical devices, Research, Science, Feinstein Institute for Medical Research, Manhasset, New York, Academic journals, Molecular Medicine, Periodicals, Publications, Kevin J. Tracey

Some of the most influential international experts, researchers, and scientific minds participated in the Fourth Bioelectronic Medicine Summit: Technology Targeting Molecular Mechanisms, hosted by The Feinstein Institutes for Medical Research the global scientific home of bioelectronic medicine on September 23 and 24.

Key Points:

Some of the most influential international experts, researchers, and scientific minds participated in the Fourth Bioelectronic Medicine Summit: Technology Targeting Molecular Mechanisms, hosted by The Feinstein Institutes for Medical Research the global scientific home of bioelectronic medicine on September 23 and 24.
Kevin Tracey, Valentin Pavlov, Sangeeta Chavan welcome participants to the 2020 Bioelectronic Medicine Summit (Credit: Feinstein Institutes)
Bioelectronic medicine combines molecular medicine, neuroscience, and biomedical engineering to develop innovative therapies to treat a variety of diseases and conditions through targeted stimulation of nerves, including paralysis, arthritis, pulmonary hypertension, and inflammatory bowel disease.
It is exciting to hear, and see first-hand from the people leading progress in bioelectronic medicine, said Valentin Pavlov, PhD , professor in the Feinstein Institutes Institute of Bioelectronic Medicine and co-chair of the summit.
We are at the forefront of a medical and technological revolution, said Sangeeta Chavan, PhD, professor in the Feinstein Institutes Institute of Bioelectronic Medicine and co-chair of the summit.

AI Can Help COVID-19 Clinical Decision Making, Feinstein Institutes Research Shows

Retrieved on:

Friday, July 10, 2020

Biotechnology, Health, Science, Research, Medical Supplies, Feinstein Institute for Medical Research, Manhasset, New York, Academic journals, Kevin J. Tracey, Molecular Medicine, Medical research, Northwell Health, Periodicals, Publications, Elmezzi Graduate School of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Those decisions, along with relevant clinical data and outcomes, could be harnessed to develop novel clinical ML tools.

Key Points:

Those decisions, along with relevant clinical data and outcomes, could be harnessed to develop novel clinical ML tools.
With abundant electronic medical data, evidence-based prediction tools can facilitate medical decision making during challenging times, said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.

Feinstein Institutes for Medical Research Finds Extended Drug Treatment Reduces Blood Clots in Discharged Patients, a Side-effect of Recovering COVID-19 Patients

Retrieved on:

Monday, June 22, 2020

Biotechnology, Infectious diseases, Hospitals, Health, Pharmaceutical, Medicine, Feinstein Institute for Medical Research, Manhasset, New York, Northwell Health, Health, Kevin J. Tracey, Rivaroxaban, Placebo, Clinical medicine

Through this research, Northwell Health has adapted its treatment policy for discharged COVID-19 patients, and others at risk, across the health system.

Key Points:

Through this research, Northwell Health has adapted its treatment policy for discharged COVID-19 patients, and others at risk, across the health system.
In the trial, a total of 4,909 patients were assigned to the rivaroxaban treatment group and 4,913 patients in the placebo group.
Dr. Spyropoulos findings provide important guidance to significantly protect patients from potentially fatal clots, said Kevin J. Tracey, MD, CEO and president of the Feinstein Institutes.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.

Feinstein Institutes CEO to Present Elsberg Lecture About Bioelectronic Medicine

Retrieved on:

Tuesday, January 28, 2020

Medical devices, Health, Hospitals, Surgery, Managed care, Clinical trials, Kevin J. Tracey, Feinstein Institute for Medical Research, Northwell Health, Nathaniel A. Elsberg, Healthcare in the United States, New York state)

The Feinstein Institutes for Medical Research President and CEO Kevin J. Tracey, MD , will present the New York Society for Neurosurgery (NYSN) 2020 Elsberg Lecture about the emerging field of bioelectronic medicine .

Key Points:

The Feinstein Institutes for Medical Research President and CEO Kevin J. Tracey, MD , will present the New York Society for Neurosurgery (NYSN) 2020 Elsberg Lecture about the emerging field of bioelectronic medicine .
View the full release here: https://www.businesswire.com/news/home/20200128005807/en/
Feinstein Institutes CEO to give Elsberg Lecture (Photo: Business Wire)
To register for the event, click here .
Dr. Traceys lecture titled, Bioelectronic Medicine The New Frontier in Neurosurgery, will expand the medical and scientific communitys knowledge of bioelectronic medicine .
Dr. Narayan is a Feinstein Institutes professor in the Institute of Bioelectronic Medicine and Northwell Healths senior vice president and executive director of neurosurgery services.